Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amlodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.98 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.98 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamlodipine SCHEMBL6664327 | 1.00 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6666635 | 1.00 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL6666638 | 1.00 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL3227613 | 0.99 | TBXA2R (0.96) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL29664887 | 0.99 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL26478 | 0.99 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL30994756 | 0.99 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL29599419 | 0.99 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL1816641 | 0.99 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL13097922 | 0.99 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828339-B2 | Aqueous solution; calcium channel blockers | SYNTHON BV (NL) | 2004-12-07 | — | — | US | disclosed |
| EP-1448197-A1 | AMLODIPINE SALT FORMS AND PROCESSES FOR PREPARING THEM | Synthon B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| US-20030139455-A1 | Amlodipine salt forms and processes for preparing them | SYNTHON IP INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003043635-A1 | AMLODIPINE SALT FORMS AND PROCESSES FOR PREPARING THEM | SYNTHON B.V. (NL) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139455-A1 | Amlodipine salt forms and processes for preparing them | CACNA1C, CACNA1D, CACNA1B | CACNA1C 1/4885TBXA2R 1024/4885ADRA1A 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.